Burning Rock Biotech (BNR) Projected to Announce Quarterly Earnings on Wednesday

Key Points

• Burning Rock Biotech is expected to report Q2 2026 results before the market opens on September 2. Analysts project a loss of $2.29 per share and revenue of approximately $19.21 million; an earnings call is scheduled for September 8.
• In the prior quarter, the company reported a loss of $0.20 per share, beating estimates, but revenue of $15.66 million fell short of expectations. The company continues to post negative profitability metrics, including a 10.98% negative return on equity.
• Analyst sentiment remains negative, with a consensus “Sell” rating. BNR shares recently traded near $9.88, well below their 52-week high of $41.72, while insiders have purchased more than 731,000 shares over the past 90 days.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($2.2883) per share and revenue of $19.2060 million for the quarter. Interested persons may visit the the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, September 8, 2026 at 12:30 PM ET.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.29) by $2.09. The business had revenue of $15.66 million for the quarter, compared to analysts' expectations of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Burning Rock Biotech Stock Performance

Shares of NASDAQ BNR opened at $9.88 on Wednesday. The firm has a market capitalization of $103.93 million, a price-to-earnings ratio of -12.05 and a beta of 1.34. Burning Rock Biotech has a one year low of $6.79 and a one year high of $41.72. The business has a fifty day simple moving average of $9.31 and a 200 day simple moving average of $15.52. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on BNR shares. Weiss Ratings raised shares of Burning Rock Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 13th. Wall Street Zen cut shares of Burning Rock Biotech from a "buy" rating to a "hold" rating in a research note on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Burning Rock Biotech currently has a consensus rating of "Sell".

Insider Activity

In other news, Director Yusheng Han purchased 24,900 shares of the business's stock in a transaction that occurred on Friday, June 26th. The stock was purchased at an average cost of $8.00 per share, with a total value of $199,200.00. Following the acquisition, the director directly owned 18,404,086 shares of the company's stock, valued at approximately $147,232,688. This trade represents a 0.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders have bought 731,410 shares of company stock worth $6,182,660. Company insiders own 30.30% of the company's stock.

Institutional Trading of Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Marshall Wace LLP bought a new stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,903 shares of the company's stock, valued at approximately $220,000. Marshall Wace LLP owned about 0.10% of Burning Rock Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 30.03% of the company's stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech NASDAQ: BNR is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company's core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source